Navigation Links
Pharmacyclics Reports Third Quarter 2013 Results
Date:11/7/2013

ients with R/R follicular lymphoma (FL) started in the second quarter of 2013. This is a multi-center, global trial of ibrutinib in patients with chemoimmunotherapy-resistant FL, whose disease has relapsed from at least 2 prior lines of therapy, including at least 1 rituximab combination chemotherapy regimen. The primary endpoint of this study is overall response rate. The enrollment target of this global study is 110 patients.
  • FLR3001: Phase III study of ibrutinib in patients with R/R indolent Non-Hodgkin's Lymphoma (iNHL) was initiated in the third quarter of 2013. This is a multi-center, global trial of ibrutinib in patients with chemoimmunotherapy-experienced FL and marginal zone lymphoma (MZL), whose disease has relapsed from at least 1 prior therapy. The primary endpoint of this study is progression free survival. The enrollment target of this global study is 400 patients.
  • WM

  • Phase II study of ibrutinib in patients with R/R Waldenstrom's Macroglobulinemia (WM) was started in the second quarter of 2012. This is a multicenter, open label study with a primary endpoint of ORR and is currently exploring ibrutinib administration at 420 mg in patients with WM who have failed at least 1 prior therapy. The study will also assess the safety and tolerability of ibrutinib as well as progression-free survival. This study is sponsored by the Dana-Farber Cancer Institute and completed enrollment of 63 patients.
  • MM

  • PCYC-1111: Phase II study of ibrutinib in patients with R/R multiple myeloma (MM) started in the first quarter of 2012. This is a Phase II, multi-center, open-label trial designed to assess the safety and efficacy of ibrutinib single agent and in combination with dexamethasone in patients with R/R MM. This study is conducted by Pharmacyclics and is currently exploring ibrutinib administration at 560 mg in combination with dexamethasone and 840 mg in combination with dexamethasone and 840 mg as a single
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

    Related medicine technology :

    1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
    2. Pharmacyclics Reports Second Quarter 2013 Results
    3. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
    4. Pharmacyclics Reports First Quarter 2013 Results
    5. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    6. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    8. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    9. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    10. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    11. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/1/2014)... 1, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Phase 3 study evaluating ISIS-SMN Rx in infants ... cause of infant mortality. Isis plans to dose the ... weeks, at which time Isis will earn an $18 ... The Phase 3 study, ENDEAR, is the first of ...
    (Date:8/1/2014)... Pa. , Aug. 1, 2014 Inovio ... will host a conference call to report its second ... at 9:00 AM ET. CEO Dr. J. Joseph ... discuss second quarter earnings, provide a corporate update, and ... will include clinical development plans for VGX-3100, Inovio,s immune ...
    (Date:8/1/2014)... Arena Pharmaceuticals, Inc. (NASDAQ: ... reported financial results for the second quarter ended ... continued to see encouraging advancements in the US ... in estimated total prescriptions and estimated total per ... Lief, Arena,s President and Chief Executive Officer. "Other ...
    Breaking Medicine Technology:Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11
    ... 2011 Quest Diagnostics Incorporated (NYSE: DGX ... and services, announced today the successful completion of its ... completed by means of a short-form merger under Delaware ... Diagnostics was merged with and into Celera, with Celera ...
    ... 2011 The U.S. Chamber of Commerce has ... CEO Mark Merritt into its elite "Association Committee ... executives. Committee members recommend Chamber policy ... collaboration, and encourage involvement in Chamber activities.  The ...
    Cached Medicine Technology:Quest Diagnostics Successfully Completes Acquisition of Celera 2
    (Date:8/1/2014)... 2014 Parker Waichman LLP, a national ... injured by defective medical devices and drugs reports that ... Ethicon surgical power morcellator devices used for the removal ... the spread of cancer associated with power morcellators, according ... 2014. , Johnson & Johnson had previously ceased ...
    (Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- Almost 140 ... school transportation in the United States. But ... bus-related catastrophes, Dawne Gardner, injury prevention coordinator at ... Center, said in a medical center news release. ... returning to school, it,s important for parents and ...
    (Date:8/1/2014)... The evolving healthcare landscape presents ... At ThoughtSpot 2014, AmerisourceBergen and Good Neighbor Pharmacy’s ... resources to enhance patient care and profitability. At ... issues to give independent pharmacists the tools they ... ThoughtSpot show attendance experienced a nearly 70% increase ...
    (Date:8/1/2014)... DC (PRWEB) August 01, 2014 ... Thompson (D-CA), Gregg Harper (R-MS), and Peter Welch ... 5380, the Medicare Telehealth Parity Act of 2014, ... fully support this effort to improve healthcare access ... chief executive officer of ATA. "These cost-saving provisions ...
    (Date:8/1/2014)... (PRWEB) August 01, 2014 On Monday, ... California NextGen User Symposium in San Francisco, CA. Now ... at the JW Marriott Union Square hotel. , “We ... get up to speed with ACA compliance issues,” Quirk ... month. The symposium provides attendees guidance with NextGen implementation ...
    Breaking Medicine News(10 mins):Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 3Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 4Health News:Expert Offers School Bus Safety Tips 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2
    ... Little League Baseball World Series, CHICAGO, Aug. ... announced the winner of its annual slogan contest ... their coaches and parents,about tobacco addiction and the ... smokeless tobacco. This year,s slogan contest winner is,Joe ...
    ... The Association of,International Automobile Manufacturers (AIAM) announced ... the Children,s Hospital,of Philadelphia (CHOP) that will provide ... involved in automobile crashes. For more than a ... scientific foundation for new,product development, improved federal motor ...
    ... http://www.TCSHealthcare.com , AUBURN, Calif., Aug. 20 ... trends in how health care professionals are ... care management,interventions. The survey results highlight the ... functionality, standardization and,interoperability to optimize clinical and ...
    ... CREEK, Calif., Aug. 20 Longs Drug,Stores Corporation ... from,continuing operations for the second quarter ended July ... share, including $0.7 million of after-tax,charges, or $0.02 ... and asset impairments and legal reserves, a 6.8 ...
    ... illegally sell alcohol, study finds , , WEDNESDAY, Aug. 20 (HealthDay ... vendors in American sports stadiums will still gladly sell you ... from a new study that suggests stadiums aren,t doing enough ... People who clearly appeared underage were able to buy alcohol ...
    ... Care as State Approves Only,Program in The Bronx, ... liver disease and need a liver transplant will no ... important follow-up,care outside the borough of the Bronx. Area ... care locally, without having to travel,long distances, as a ...
    Cached Medicine News:Health News:Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use 2Health News:AIAM Sponsors Leading Child Safety Research Initiative 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Longs Drug Stores Corporation Reports Second Quarter Results 2Health News:Longs Drug Stores Corporation Reports Second Quarter Results 3Health News:Longs Drug Stores Corporation Reports Second Quarter Results 4Health News:Longs Drug Stores Corporation Reports Second Quarter Results 5Health News:Longs Drug Stores Corporation Reports Second Quarter Results 6Health News:Longs Drug Stores Corporation Reports Second Quarter Results 7Health News:Longs Drug Stores Corporation Reports Second Quarter Results 8Health News:Longs Drug Stores Corporation Reports Second Quarter Results 9Health News:Longs Drug Stores Corporation Reports Second Quarter Results 10Health News:Longs Drug Stores Corporation Reports Second Quarter Results 11Health News:Longs Drug Stores Corporation Reports Second Quarter Results 12Health News:Longs Drug Stores Corporation Reports Second Quarter Results 13Health News:Underaged, Inebriated Easily Get Drinks at Stadiums 2Health News:Liver Transplant Program Established At Montefiore 2Health News:Liver Transplant Program Established At Montefiore 3Health News:Liver Transplant Program Established At Montefiore 4
    ... This equipment is a fundus ... mydriatic and non-mydriatic photography with ... 25 (45 and 22 for ... photographic data with 35-mm film,Polaroid ...
    ... practice management software is a full-featured ... and clinical aspects of the ophthalmic ... support for the financial, administrative and ... care professional. Designed as a scaleable ...
    ... Medical Systems Information Technologies ... for yourself how it's ... Office - Practice Management ... can simplify your office ...
    ... Retinal Camera System is an easy-to-use digital ... images for documentation, diagnosis and patient education. ... camera for optimal performance. We also offer ... anterior segment images. ReSeeVit is a true ...
    Medicine Products: